Transthyretin Amyloidosis Treatment Market Growth Outlook to $7.42 Billion by 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Transthyretin Amyloidosis Treatment Market From 2026 To 2030?
The transthyretin amyloidosis treatment market has shown strong expansion in recent years. It is anticipated to increase from $4.96 billion in 2025 to $5.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The growth observed in prior periods can be attributed to heightened recognition of hereditary amyloidosis, wider availability of genetic testing, the introduction of disease-modifying medications, better specialist referral systems, and the proliferation of rare disease registries.
The transthyretin amyloidosis treatment market is projected to experience robust expansion in the coming years. This market is set to reach $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period is propelled by factors such as the progress in next-generation attr therapies, greater investments in pipeline and combination treatments, wider availability of specialty pharmacies, an increasing need for personalized therapy choices, and sustained growth in clinical trial activities. Key trends anticipated within this period encompass the escalating development of targeted attr therapies, increased uptake of gene silencing medications, a heightened emphasis on managing multisystem diseases, the broadening of pipeline therapies for attr variants, and enhanced patient stratification and monitoring processes.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Which Important Drivers Are Guiding The Transthyretin Amyloidosis Treatment Market Growth?
Increased spending on research and development (R&D) is anticipated to boost the expansion of the transthyretin amyloidosis treatment market moving forward. These R&D investments signify financial resources dedicated to discovering new therapies, improving existing treatments, and advancing scientific understanding across various disease areas. Funding for R&D is on the rise as governments and private sectors intensify their focus on rare diseases, precision medicine, and next-generation therapeutic platforms. Such rising investments accelerate the discovery and progression of innovative therapies, enhancing treatment options and outcomes for transthyretin amyloidosis patients. For instance, in November 2023, a report from the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade association, indicated that pharmaceutical industry research and development expenditure rose to 50,000 million in 2023, up from 47,010 million in 2022. Thus, increasing research and development investments are indeed propelling the growth of the transthyretin amyloidosis treatment market.
How Is Segmentation Applied In The Transthyretin Amyloidosis Treatment Market Segment Analysis?
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
What Trends Are Influencing The Evolution Of The Transthyretin Amyloidosis Treatment Market?
Leading companies in the transthyretin amyloidosis treatment market are concentrating on the development of innovative and specialized therapies, such as orphan drugs, with the aim of improving patient outcomes and expanding treatment options. Eplontersen stands as an orphan drug specifically formulated for the transthyretin amyloidosis condition, often receiving regulatory advantages to facilitate its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, obtained Food and Drug Administration (FDA) approval for a new drug application pertaining to Eplontersen, an experimental orphan drug designated for the management of familial transthyretin-mediated amyloid, which results in progressive polyneuropathy. Eplontersen functions as a pharmaceutical agent designed to lessen the synthesis of transthyretin (TTR) protein, thereby addressing both hereditary and non-hereditary forms of ATTR amyloidosis (amyloid transthyretin amyloidosis).
Who Are The Companies Participating In The Transthyretin Amyloidosis Treatment Market Environment?
Major companies operating in the transthyretin amyloidosis treatment market are Pfizer Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals, Prothena Corporation plc, Eidos Therapeutics Inc, BridgeBio Pharma Inc, Neurimmune AG, AstraZeneca plc, Intellia Therapeutics Inc, Novo Nordisk A/S, YolTech Therapeutics Co Ltd, Life Molecular Imaging GmbH, Attralus Inc, Regeneron Pharmaceuticals, Silence Therapeutics, Proclara Biosciences, Corino Therapeutics, SOM Biotech, Oncopeptides AB, Takeda Pharmaceutical Company Limited, Horizon Therapeutics, Roche Holding AG, SOM Innovation Biotech SA
Get The Full Transthyretin Amyloidosis Treatment Market Report:
Which Geographic Region Dominates The Transthyretin Amyloidosis Treatment Market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2025. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Transthyretin Amyloidosis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Transthyretin Amyloidosis Treatment Market 2026, By The Business Research Company
Atrophic Glossitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report
Keloids Treatment Market Report
https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report
Pigmentation Disorders Treatment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
